scholarly journals Closure of Interatrial Septal Communications: Adverse Events and Lessons Learned

10.4021/cr17w ◽  
2011 ◽  
Author(s):  
Wagdi
Keyword(s):  
Adverse Events ◽  
Lessons Learned

Sharing Lessons Learned to Prevent Adverse Events in Anesthesiology Nationwide

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Christina Soncrant ◽  
Julia Neily ◽  
Sam John T. Sum-Ping ◽  
Arthur W. Wallace ◽  
Edward R. Mariano ◽  
...  
Keyword(s):  
Adverse Events ◽  
Lessons Learned

Successes with and barriers to patient-reported outcome deployment at a comprehensive cancer center.

2018 ◽  
Vol 36 (30_suppl) ◽  
pp. 292-292
Author(s):  
Nadine Jackson McCleary ◽  
Deborah Schrag ◽  
Neil E. Martin ◽  
Sadiqa Mahmood ◽  
Elizabeth Beyer ◽  
...  
Keyword(s):  
Adverse Events ◽  
Assessment Tool ◽  
Treatment Plan ◽  
Patient Reported Outcome ◽  
Lessons Learned ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Patient Reported ◽  
Oncology Practice ◽  
Plan Modification

292 Background: Routine collection of patient reported outcomes (PROs) reduces hospitalizations and improves quality of life. In the absence of clear implementation guidelines and research guiding deployment, PROs may not have the desired impact on outcomes in routine oncology practice. We share lessons learned from PRO deployment at Dana-Farber Cancer Institute. Methods: We developed a symptom/toxicity assessment tool based on the PRO-CTCAE to capture 15 symptomatic adverse events with a 1-week recall: fatigue/ decreased appetite/insomnia/ shortness of breath/numbness and tingling/concentration, general pain/anxiety/sadness, rash, nausea/vomiting/fever, constipation, and diarrhea. Responses from eligible English-literate patients scheduled for a gastrointestinal cancer center or adult palliative care visit between January 18 to March 22, 2018 were transmitted directly from clinic tablet to the EMR. To evaluate the deployment, we sought qualitative feedback from clinic staff and three multidisciplinary working groups comprised of patients, nurses, pharmacists, operations leaders, quality/safety experts, and health services researchers to identify technical and workflow gaps in PRO Content, Implementation, and Analytics. Results: We noted a 38% response rate of the N = 4440 PROs assigned to N = 4440 scheduled visits for N = 2055 unique patients (36% were completed, 2% started but not completed); 62% were not started. Workflow enhancement requests include an updated summary view, a clinical documentation tool, a scoring algorithm to highlight severe responses, and a quality metric dashboard to evaluate the deployment. Ongoing analyses are studying the proportion of moderate-severe symptomatic adverse events reported and their association with provider action (i.e., supportive care referral, chemotherapy treatment plan modification, or unplanned ED/hospitalization in the subsequent 30 days). Conclusions: Refinement of the PRO deployment strategy is needed to guide implementation efforts and demonstrate meaningful impact in routine oncology practice.

scholarly journals Lessons learned for reducing the negative impact of adverse events on patients, health professionals and healthcare organizations

2017 ◽  
Vol 29 (4) ◽  
pp. 450-460 ◽  
Author(s):  
JOSE JOAQUIN MIRA ◽  
SUSANA LORENZO ◽  
IRENE CARRILLO ◽  
LENA Ferrús ◽  
CARMEN SILVESTRE ◽  
...  
Keyword(s):  
Adverse Events ◽  
Health Professionals ◽  
Negative Impact ◽  
Lessons Learned ◽  
Healthcare Organizations

Anesthesia Adverse Events Voluntarily Reported in the Veterans Health Administration and Lessons Learned

2018 ◽  
Vol 126 (2) ◽  
pp. 471-477 ◽  
Author(s):  
Julia Neily ◽  
Elda S. Silla ◽  
Sam (John) T. Sum-Ping ◽  
Roberta Reedy ◽  
Douglas E. Paull ◽  
...  
Keyword(s):  
Adverse Events ◽  
Veterans Health Administration ◽  
Lessons Learned ◽  
Veterans Health ◽  
Health Administration

scholarly journals Synthetic ACTH for Treatment of Glomerular Diseases: A Case Series

2022 ◽  
Vol 9 ◽  
pp. 205435812110669
Author(s):  
Arenn Jauhal ◽  
Bhanu Prasad ◽  
Mathieu Rousseau-Gagnon ◽  
Gabriel Ouellet ◽  
Michelle A Hladunewich
Keyword(s):  
Adverse Events ◽  
Adrenocorticotropic Hormone ◽  
Minimal Change Disease ◽  
Case Series ◽  
Minimal Change ◽  
Lessons Learned ◽  
Focal And Segmental Glomerulosclerosis ◽  
Glomerular Diseases ◽  
Conservative Care ◽  
Segmental Glomerulosclerosis

Rationale: Synthetic adrenocorticotropic hormone (Tetracosactide) has been used in the treatment of refractory glomerular diseases. Literature surrounding the use of this medication is limited to small case series and there is conflicting data on the rate of adverse events associated with this medication. Presenting concerns of the patient: Glomerulonephritis not in remission after at least 6 months of treatment with conservative care. Stable doses of concurrent immunosuppression were permitted. Diagnoses: Membranous nephropathy, IgA nephropathy, minimal change disease, and focal and segmental glomerulosclerosis. Intervention: Intramuscular synthetic adrenocorticotropic hormone (Tetracosactide, Synacthen Depot) with doses of either 1 mg weekly or 1 mg twice weekly. Outcomes: Five of 12 patients had at least a partial remission with Tetracosactide. Median time to response was 6 months for responders. Five of the 12 patients had adverse events documented, 2 of which led to treatment discontinuation. No patients with focal and segmental glomerulosclerosis responded to treatment. Lessons Learned: Higher rate of adverse events than previously reported with synthetic adrenocorticotropic hormone and uncertain treatment efficacy.

Sign in / Sign up

Export Citation Format

Share Document